BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2

We have recently observed a 41-year-old woman who developed chilblain-like lesions (CLL) soon after the second administration of Pfizer BNT162b2 mRNA Covid-19 Vaccine. The lesions occurred exclusively on the volar aspects of the second and the third fingertip of right hand. The latency between the administration of the second dose of vaccine and the occurrence of CLL was 24 hours. The lesions were extremely painful.

[1]  P. de Truchis,et al.  ‘Blue toes’ following vaccination with the BNT162b2 mRNA COVID-19 vaccine , 2021, Journal of travel medicine.

[2]  M. Cutrone,et al.  Chilblain‐like lesions and COVID‐19: second wave, second outbreak , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  T. Russo,et al.  Chilblain-Like Lesions during COVID-19 Pandemic: The State of the Art , 2021, Life.

[4]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[5]  G. Leftheriotis,et al.  Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic. , 2020, JAMA dermatology.

[6]  G. Argenziano,et al.  Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: A multicenter study on 10 patients , 2020, Journal of American Academy of Dermatology.

[7]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[8]  V. Piccolo,et al.  Chilblain‐like lesions during the COVID‐19 pandemic: should we really worry? , 2020, International journal of dermatology.

[9]  V. Piccolo,et al.  Acral findings during the COVID-19 outbreak: Chilblain-like lesions should be preferred to acroischemic lesions , 2020, Journal of the American Academy of Dermatology.

[10]  G. Argenziano,et al.  Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.